eNeura Therapeutics

What eNeura Therapeutics does

eNeura Therapeutics operates as a prescription medical device company developing single-pulse transcranial magnetic stimulation (sTMS) technology for the treatment of migraine. The company's core platform, sTMS, delivers brief magnetic pulses targeting the occipital cortex to modulate hyperactive neural activity associated with migraine, and is the only FDA-cleared central neuromodulation therapy indicated for both acute and preventive treatment in patients aged 12 and older. Its product portfolio comprises SAVI Dual for the US market, sTMS mini for the UK market, and the sTMS Smart Diary, a HIPAA-compliant cloud platform that automatically uploads treatment history to enable remote therapeutic monitoring.

The company operates as a subsidiary of Aruene Corporation, with US headquarters in West Palm Beach, Florida, an additional US office in Baltimore, Maryland, and a UK entity in Didcot, Oxfordshire. Its go-to-market is prescription-driven: patients obtain sTMS prescriptions from neurologists, headache specialists, or telehealth providers, and devices ship directly to the patient's home. Revenue is generated through monthly subscription fees (with insurance-based pricing variation) and one-time hardware activations, including dedicated VA Federal Supply Schedule contracts through SDVOSB distributor Recon Spine. eNeura serves migraine patients, healthcare providers, US veterans via the VA Headache Centers of Excellence program, and UK patients via NHS and private consultant neurologist channels.

The company is privately held with cumulative disclosed funding of approximately $75 million across 14 rounds from 2002 to 2019, with no public capital events since late 2019. Leadership includes Chairman David K. Rosen, CEO Spencer F. Segura, and a clinical sales team led by VP of Sales Eric Bohlen. Notable strategic positioning includes the pursuit of FDA Breakthrough Device Designation for Major Depressive Disorder, signaling potential expansion beyond migraine into adjacent CNS indications.

Name

eNeura Therapeutics

Legal name

Aruene Corporation dba eNeura Inc.

Website

https://eneura.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

11–50 employees

Short description

eNeura Therapeutics is a prescription medical device company offering FDA-cleared single-pulse transcranial magnetic stimulation (sTMS) therapy for acute and preventive migraine treatment, serving patients, healthcare providers, US veterans, and UK consumers via subscription-based home-delivered devices.

Ownership category

akta.pro rank

Product category

Neuromodulation Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical and Medical Instrument Manufacturing (339112)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS) (HLAHAEAK)

Keywords

• Transcranial magnetic stimulation
• Migraine medical devices
• Neuromodulation therapy
• Prescription digital therapeutics
• Non-invasive brain stimulation

Headquarters

HQ city

Sunnyvale

HQ country

United States

HQ region

North America

Offices5 records

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Others

Revenue model

1. sTMS Device / Prescription Fee (Monthly): SAVI Dual sTMS Therapy is available through a convenient monthly prescription. Each prescription includes unlimited acute and preventive treatments, personalized clinical specialist support, and smart neuromodulation technology with automated diary. Monthly fee varies based on insurance coverage. The subscription model includes direct access to eNeura Customer Care and Clinical Support. Auto-renewal monthly subscription after initial 3-month period.
2. Device Sales (One-time or Subscription Activation): sTMS is shipped directly to the patient's home upon prescription approval. VA ordering uses FSS activation codes: 3-month activation (Item #16140-0020-13-3) and 12-month activation (Item #16140-0020-13-12). FSA and HSA accounts accepted for payment.

Pricing tiers

Distribution channels5 records

Marketing channels7 records

Core offering

eNeura Therapeutics develops, manufactures, and sells prescription Single-Pulse Transcranial Magnetic Stimulation (sTMS) medical devices for the acute treatment and prevention of migraine. Its flagship products are SAVI Dual (FDA-cleared, US market) and sTMS mini (CE-marked, UK market), which deliver brief, non-invasive magnetic pulses through the cortex to quiet hyperactive nerves associated with migraine. The company sells the therapy via monthly prescription subscription with a companion sTMS Smart Diary cloud-based HIPAA-compliant application that automatically tracks and transmits treatment history for Remote Therapeutic Monitoring.

Product overview

eNeura Therapeutics offers a single-pulse transcranial magnetic stimulation (sTMS) platform for migraine treatment. The core product line consists of SAVI Dual (US market) and sTMS mini (UK market) — prescription medical devices that deliver non-invasive brain stimulation to treat acute migraine attacks and prevent future migraine days. The company also provides the companion sTMS Smart Diary cloud-based application that automatically syncs with the device to track treatment history and monitor patient progress. The sTMS platform is FDA-cleared for both acute and preventive treatment of migraine in adults and adolescents aged 12 and older.

Differentiator

Problem solved

Functional benefit

Brands

• SAVI Dual: FDA-cleared dual migraine therapy device providing acute and preventive sTMS treatment for migraine in patients 12 and older.
• sTMS mini
• SAVI Smart Diary

Products and services

• SAVI Dual sTMS Migraine Therapy FDA-cleared, non-invasive Single-Pulse Transcranial Magnetic Stimulation (sTMS) prescription medical device for adults and adolescents 12+ in the US market, providing both acute treatment of migraine attacks at onset and daily preventive therapy to reduce migraine days. Includes cloud-based treatment history tracking and is sold as a monthly prescription subscription with Clinical Specialist support.
• sTMS mini Migraine Therapy Portable Single-Pulse Transcranial Magnetic Stimulation (sTMS) prescription medical device marketed in the United Kingdom for acute treatment and prevention of migraine attacks in patients, prescribed by consultant neurologists via NHS and private channels and supported by eNeura UK Customer Care.

Quantifiable outcome

• In a study of people using sTMS to treat migraines, more people using sTMS experienced pain freedom and freedom from bothersome migraine symptoms at 2 hours versus placebo, with benefits sustained through 48 hours
• +2 more outcomes

Named customers1 record

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Three partnerships are on record, tiered core and minor.

• Recon Spine LLC (DBA Recon Supply)coreChannel Partner/ Reseller/ DistributorRecon Spine is a Service-Disabled Veteran-Owned Small Business (SDVOSB) distributor for eNeura's VA Federal Supply Schedule program. Handles distribution of sTMS Migraine Therapy to US veterans through the VA Healthcare System. Contact: [email protected], Phone: 314-610-2334, Fax: 636-206-5220, FSS Number: 36F79720D0009.
• Telehealth Providers (Teladoc, MDLIVE, CVS, Amazon One Medical)minorChannel Partner/ Reseller/ DistributoreNeura partners with major telehealth providers including Aetna, Anthem Blue Cross Blue Shield, Cigna, United Healthcare, Amazon One Medical, CVS, MDLIVE, and Teladoc to facilitate online consultations where patients can connect with healthcare providers to obtain sTMS prescriptions.
• Insurance Companies (Aetna, Anthem BCBS, Cigna, United Healthcare)minorChannel Partner/ Reseller/ DistributorTop telehealth providers listed include major insurance companies' telemedicine platforms (Aetna, Anthem BCBS, Cigna, United Healthcare) where members can access virtual care consultations, including potentially for sTMS prescriptions.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• electroCore: Developer of gammaCore (non-invasive vagus nerve stimulation), FDA-cleared for migraine, cluster headache and several other indications. Direct rival in neuromodulation-based migraine therapy.
• Cefaly: Manufactures the Cefaly device, an external trigeminal nerve stimulation device FDA-cleared for migraine prevention and acute treatment. Competes in the same prescription neurostimulator category for migraine.
• Theranica Bio-Electronics: Maker of Nerivio, an FDA-cleared wearable neuromodulation device indicated for acute and preventive treatment of migraine. Direct competitor in non-invasive, app-connected migraine neuromodulation.

Broad incumbents

• AbbVie: Through the Allergan acquisition, markets Botox for chronic migraine and UBRELVY (gepant) for acute migraine. Both a direct therapeutic competitor to sTMS and the prior standard before which NHS positions eNeura.
• Teva Pharmaceutical Industries: Markets Ajovy, an anti-CGRP monoclonal antibody for migraine prevention. A large-pharma incumbent competing for the same migraine prescription and reimbursement share as eNeura.
• Amgen: Markets Aimovig, the first FDA-approved CGRP monoclonal antibody for migraine prevention. A large-cap incumbent setting the dominant therapeutic class competing against neuromodulation.
• Medtronic: Diversified neuromodulation leader with DBS, SCS and PNS platforms. Broad incumbent offering overlapping central and peripheral neurostimulation technology that informs the category competitive set.
• Biohaven Pharmaceuticals: Developer of Nurtec ODT, a CGRP receptor antagonist for acute and preventive migraine. Recently acquired by Pfizer, representing a significant incumbent channel competitor for migraine prescriptions.
• Eli Lilly: Markets Emgality, a CGRP monoclonal antibody for migraine prevention, and has pipeline assets in migraine. A large-pharma incumbent competing for migraine patient share and prescriber mindshare.

Emerging players

• Curelator: Listed alongside eNeura as a key player in the Digital Therapeutics Medical Devices for Migraine Market; data-driven migraine management platform with partial overlap in migraine patient engagement.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/savidual
• Facebookfacebook.com/profile.php?id=61553301180397
• LinkedInlinkedin.com/company/eneura-therapeutics
• Instagraminstagram.com/eneura_savi_dual

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds14 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about eNeura Therapeutics